脑膜瘤药物治疗的研究进展  

Research progress in drug therapy for meningiomas

作　　者：孙亚雪 谢春美 赵庚水 张文超[1] SUN Ya-xue;XIE Chun-mei;ZHAO Geng-shui;ZHANG Wen-chao(Department of Neurosurgery,Harrison International Peace Hospital,Hengshui 053000,China)

机构地区：[1]哈励逊国际和平医院神经外科,河北衡水053000

出　　处：《中国临床神经外科杂志》2024年第3期181-184,共4页Chinese Journal of Clinical Neurosurgery

摘　　要：脑膜瘤是常见的颅内肿瘤,不适合手术或放疗等治疗的复发性脑膜瘤的治疗仍然是一项临床挑战。由于缺乏证据,脑膜瘤的药物治疗方案在很大程度上仍处于实验阶段,疗效和临床益处的证据有限。目前,细胞毒性药物、激素受体抑制剂及类似物疗效有限,靶向制剂、免疫检查点抑制剂、酪氨酸激酶抑制剂、表观遗传学相关药物等则表现出更好的临床治疗反应。本文总结脑膜瘤药物治疗方案的现有证据,并概述目前研究的药物和未来前景。Meningiomas are common intracranial tumors,and the treatment of recurrent meningiomas that are not suitable for surgery or radiation therapy remains a clinical challenge.Due to a lack of evidence,the drug treatment regimen for meningiomas is largely still in the experimental stage,with limited evidence of therapeutic efficacy and clinical benefit.Currently,the efficacy of cytotoxic drugs,hormone receptor inhibitors,and their analogues is limited,while targeted agents,immune checkpoint inhibitors,tyrosine kinase inhibitors,and epigenetic-related drugs have shown better clinical therapeutic responses.This article summarizes the existing evidence on drug treatment regimens for meningiomas and outlines the current drugs and future prospects under investigation.

关 键 词：脑膜瘤 药物治疗 靶向制剂 酪氨酸激酶抑制剂 免疫检查点抑制剂 

分 类 号：R739.41[医药卫生—肿瘤]